German specialty pharma group Grunenthal has agreed to acquire Bayer’s cancer medicine Stivarga (regorafenib) for up to EUR 375 million, adding an established oral oncology asset that is already approved in more than 90 markets. For buyers and sellers of mature specialty brands, the deal is a clean read on how late-lifecycle oncology products are being repriced when commercial scale, not discovery pipeline, is the scarce resource.
What happened
On 21 September 2026, Grunenthal announced an agreement with Bayer AG to buy Stivarga, an oral multikinase inhibitor used in selected advanced cancers after prior therapy. Indications covered in major labels include metastatic colorectal cancer, gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma. Closing is targeted for late 2026 or early 2027, subject to customary conditions and regulatory clearances.
Stivarga has treated more than one million patients over roughly a decade and remains available across a broad geographic footprint. Loss of exclusivity is anticipated in 2029 in the European Union and in 2030 in the United States, so the buyer is underwriting roughly three to four years of branded cash flow plus whatever lifecycle management it can execute after patent cliffs begin.
Grunenthal frames the purchase as immediately accretive and estimates a positive consolidated EBITDA contribution of up to about EUR 100 million for the year ending 31 December 2027, assuming close by end-2026 or early 2027 and full-year consolidation. That guidance is management-derived from information provided in diligence; it is a planning marker, not a guarantee of run-rate earnings.
The transaction sits inside a longer M&A pattern. Since 2017 Grunenthal says it has invested around EUR 2.6 billion in successful deals spanning established medicines such as Nebido, regional Cialis rights, European Crestor and Nexium rights, Vimovo, Zomig, Qutenza, and the 2024 Valinor Pharma / Movantik package, plus full ownership of the former Grunenthal Meds joint venture with Kyowa Kirin International. In 2025 the group employed about 4,100 people and reported revenues of EUR 1.8 billion, with affiliates in 28 countries.
Why it matters
Big Pharma continues to prune non-core brands while specialty and mid-size players bid for durable prescription cash flows they can detail harder than a diversified major. Stivarga is not a Phase 2 story; it is a commercialized oral oncology product with known safety, reimbursement pathways, and a finite exclusivity clock. That profile attracts operators who specialize in maximizing late-lifecycle brands rather than funding first-in-class discovery.
For oncology channel economics, the deal reinforces three structural points. First, oral multikinase inhibitors still matter in later-line colorectal, GIST, and liver cancer algorithms even as immuno-oncology and ADCs reshape earlier lines. Second, geographic breadth (90-plus markets) can matter as much as peak share in any single country when a buyer already runs affiliates across Europe, Latin America, and the United States. Third, LOE timing in 2029-2030 sets a clear window for price, access, and authorized-generic strategy before generics compress the franchise.
Investors watching pharma portfolio rotation should also note the seller side. Bayer is recycling capital from an established oncology product into higher-priority assets, while Grunenthal is concentrating capital where its commercial engine is strongest. That division of labor – discovery-heavy majors exiting, commercial-heavy specialists entering – is becoming a repeatable pattern in European specialty M&A.
Teams mapping adjacent category demand can cross-check hospital and outpatient therapy themes in our Healthcare & Medical Devices shelf, and feedstock and formulation linkages under Chemicals & Materials.
Who feels it
Specialty pharma business development teams gain another comps point for late-lifecycle oncology assets priced in the mid-hundreds of millions of euros with near-term EBITDA accretion claims.
Oncology distributors, specialty pharmacies, and hospital pharmacies should track label ownership changes that can alter tendering, medical-affairs coverage, and patient-support programs without changing the molecule.
Payers and HTA bodies in the EU and US will care less about the corporate logo and more about whether the new owner sustains supply, pharmacovigilance, and any outcomes or access schemes tied to Stivarga.
Generic and authorized-generic planners will mark 2029 (EU) and 2030 (US) as the LOE waypoints that determine when competitive oral formulations can contest volume.
Bayer oncology franchise managers must ring-fence remaining priority assets and communicate cleanly to physicians so prescription continuity does not slip during the transition.
What to watch
Four checkpoints will decide whether this deal is a quiet bolt-on or a template for the next wave of established-medicine oncology sales:
- Regulatory clearances and close timing – whether end-2026 / early-2027 holds, because the EUR 100 million 2027 EBITDA sketch assumes prompt consolidation.
- Commercial handover quality – medical information, tender contracts, and affiliate detailing must transfer without disrupting later-line oncology scripts.
- Pre-LOE lifecycle moves – any new combinations, formulations, or access programs before 2029-2030 exclusivity cliffs.
- Follow-on Bayer divestitures – if more mature brands are shopped, mid-size European buyers will treat Stivarga as a pricing anchor.
For the buyer narrative and deal framing straight from the acquirer, start with Grunenthal corporate materials at grunenthal.com, then overlay your own LOE calendars and affiliate-level volume data. The strategic question is simple: can a focused commercial owner extract more value from a known oral oncology brand in the final exclusivity years than a diversified major can?